Saira Ramasastry - May 26, 2021 Form 3 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
May 26, 2021
Transactions value $
$0
Form type
3
Date filed
5/26/2021, 09:06 PM
Previous filing
May 25, 2021
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DAWN Common Stock 50.5K May 26, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DAWN Stock Option (right to buy Common Stock) May 26, 2021 Common Stock 40K $16.00 Direct F2
holding DAWN Stock Option (right to buy Common Stock) May 26, 2021 Common Stock 47.6K $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F2 The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The option vests as to 1/48th of the total shares on each monthly anniversary, beginning on May 6, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.